Nasdaq

GE HealthCare unveils Pristina Recon DL for mammography – deep learning image reconstruction technology delivering clearer image quality

GE HealthCare has received FDA Premarket Authorization for Pristina Recon DL, an innovative 3D mammography reconstruction application. Powered by artificial intelligence (AI), Pristina Recon DL ...
Nasdaq

GE HealthCare Introduces Sonic DL: A Groundbreaking, FDA-Cleared AI Deep Learning Technology for Faster MRI

Sonic DLi is a deep learning (DL) technology that acquires high-quality magnetic resonance (MR) images up to 12 timesii faster than conventional methods, enabling cardiac imaging within a single ...

AIRS Medical's SwiftMR(R) Receives FDA Clearance to Work in Conjunction with OEM Deep Learning Reconstruction Solutions

AIRS Medical today announced that SwiftMR(R), an FDA 510(k)-cleared, vendor-neutral MRI image enhancement solution, has received clearance to operate in conjunction with deep learning (DL) ...
Business Wire

GE HealthCare Unveils Sonic DL for 3D, Expanding Deep Learning Innovations in MRI

New 3D imaging capabilities of Sonic DL are designed to enable up to 86% i faster scans and enhanced resolution for brain, spine, orthopedic and body imaging. Combination of Sonic DL and AIR Recon DL ...
Business Wire

GE HealthCare Expands Its Effortless Recon DL Portfolio, Bringing Advanced Deep Learning Image Reconstruction to Clinicians Worldwide

More than 80 percent of all health system visits include an imaging exam, i making radiology an essential part of diagnostics and healthcare and image quality a cornerstone of medicine. GE HealthCare ...
News Medical

Using Deep Learning for Brain Imaging Data Analysis

Deep learning (DL) is a type of artificial intelligence (AI) that utilizes artificial neural networks (ANNs) to process data through two or more layers, each of which can recognize complex features of ...
ascopubs.org

A novel application of deep learning (DL)-based MRI with liquid biomarkers for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor ...

An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors. This is an ASCO Meeting ...

AIRS Medical's SwiftMR® Receives FDA Clearance to Work in Conjunction with OEM Deep Learning Reconstruction Solutions

AIRS Medical today announced that SwiftMR®, an FDA 510(k)-cleared, vendor-neutral MRI image enhancement solution, has received clearance to operate in conjunction with deep learning (DL) ...